Table 2.
Treatment characteristics of included trials.
| Author (year) | Treatment arm(s) | SCRT chemotherapy regimen | CCRT chemotherapy regimen | Radiation dose fractionation |
|---|---|---|---|---|
| Antonadou (2002) | CCRT, SCRT, cRT | Platinum based | – | 55–60 Gy/27–30# ± 5-10 Gy Boost |
| Antonia (2017) | CCRT | – | Platinum based | 54–60 Gy/27–30# |
| Atagi (2012)† | CCRT, cRT | – | Carboplatin | 60 Gy/30# |
| Ball (2019) | cRT | – | – | 66 Gy/33# or 50 Gy/20# |
| Belani (2005a) | SCRT | Carboplatin/paclitaxel | – | 64 Gy/32# or 57.6 Gy/36# TDS |
| Belani (2005b) | CCRT, SCRT | Carboplatin/paclitaxel | Carboplatin/paclitaxel | 63 Gy/34# |
| Belderbos (2007) | CCRT, SCRT | Cisplatin/gemcitabine | Cisplatin | 66 Gy/24# |
| Bezjak (2002) | pRT | – | – | 20 Gy/5# or 10 Gy/1# |
| Bradley (2015) | CCRT | Carboplatin/paclitaxel | Carboplatin/paclitaxel | 74 Gy/37# or 60 Gy/30# |
| Cakir (2004) | CCRT, cRT | – | Cisplatin | 64 Gy/32# |
| Crvenkova (2018) | CCRT, SCRT | Carboplatin/paclitaxel, carboplatin/etoposide | Cisplatin/etoposide | 60 Gy/30# |
| Curran (2011) | CCRT, SCRT | Cisplatin/vinblastine | Cisplatin/etoposide or cisplatin/Vinblastine | 69.6 Gy/58# BD or 60 Gy/30# |
| Edelman (2017) | CCRT | Carboplatin | Carboplatin/paclitaxel | 60 Gy/30# |
| Erridge (2005) | pRT | – | – | 30 Gy/10# or 10 Gy/1# |
| Fairlamb (2005) | CCRT, SCRT | Cisplatin based | – | 50–55 Gy/20# |
| Falk (2002) | pRT | – | – | 17 Gy/2# weekly or 10 Gy/1# |
| Feng (2016) | CCRT | – | Cisplatin | 60 Gy/30# |
| Fournel (2005) | CCRT, SCRT | Cisplatin/vinorelbine | Cisplatin/etoposide | 66 Gy/33# |
| Fournel (2016) | CCRT | Cisplatin/paclitaxel | Cisplatin/vinorelbine | 66 Gy/33# |
| Gouda (2006) | CCRT, cRT | Carboplatin/paclitaxel | Carboplatin/paclitaxel | 60 Gy/30# |
| Hanna (2008) | CCRT | Docetaxel | Cisplatin/etoposide | 59.4 Gy/33# |
| Hansen (2017) | CCRT | Carboplatin/vinorelbine | Vinorelbine | 66 Gy/33# or 60/30# |
| Huber (2006) | CCRT, SCRT | Carboplatin/paclitaxel | Paclitaxel | 60–66 Gy/30–33# |
| Jalal (2012) | CCRT | Docetaxel | Cisplatin/etoposide | 59.4 Gy/33# |
| Johnstone 2002) | SCRT | Cisplatin/mitomycin-C±vinblastine | – | 64 Gy/32# |
| Kelly (2008) | CCRT | Docetaxel | Cisplatin/etoposide | 61 Gy/33# |
| Kramer (2005) | pRT | – | – | 30 Gy/10# or 16 Gy/2# weekly |
| Lee (2017) | CCRT | Cisplatin/Irinotecan | Cisplatin/irinotecan | 60 Gy/30# |
| Liang (2017) | CCRT | – | Cisplatin/etoposide or carboplatin/paclitaxel | 60–66 Gy/30–33# |
| Lu (2010) | CCRT | Carboplatin, cisplatin/vinorelbine | Carboplatin/paclitaxel or cisplatin/vinorelbine | 60 Gy/30# |
| Movsas (2010) | CCRT | Gemcitabine, gemcitabine/docetaxel | Cisplatin/etoposide | 62 Gy/31# |
| Nawrocki (2010) | pRT | – | – | 30 Gy/10# |
| Nestle (2000) | cRT, pRT | – | – | 60 Gy/30# or 32 Gy/16# BD |
| Nyman (2016) | cRT | – | – | 70 Gy/35# |
| Pan (2016) | CCRT | Carboplatin/vinorelbine | Vinorelbine | 66 Gy/33# or 60 Gy/30# |
| Reinfuss (2005) | CCRT, SCRT | Cisplatin/navelbine | Cisplatin/navelbine | 70.2 Gy/39# |
| Sasaki 2018) | CCRT | – | Cisplatin/S1 or cisplatin /vinorelbine | 60 Gy/30# |
| Scagliotti (2006) | CCRT, SCRT | Cisplatin/docetaxel | Docetaxel | 60 Gy/30# |
| Sculier (2018) | CCRT | Cisplatin/docetaxel | Cisplatin/docetaxel | 66 Gy/33# |
| Senan (2016) | CCRT | Platinum based doublet, premetrexed | Cisplatin/etoposide or cisplatin/pemetrexed | 60–66 Gy/30–33# |
| Senkus-Konefka (2005) | pRT | – | – | 20 Gy/5# or 16 Gy/2# weekly |
| Shibamoto (2001) | CCRT | – | Carboplatin/etoposide | 69.6 Gy/58# BD |
| Su (2019) | CCRT | – | Cisplatin/premetrexed or cisplatin/docetaxel | 40 Gy/20# + 20–30 Gy/1.5 Gy BD |
| Sundstrom (2004) | cRT, pRT | – | – | 50 Gy/25# or 42 Gy/15# or 17 Gy/2# |
| Takigawa (2011) | CCRT | – | Cisplatin/docetaxel or cisplatin/mitomycin/vindesine | 60 Gy/30# |
| van Diessen (2019) | CCRT | – | Cisplatin based | ≥ 72 Gy/24# |
| Vokes (2002) | CCRT | Cisplatin/gemcitabine, paclitaxel, vinorelbine | Cisplatin based | 66 Gy/33# |
| Yamamoto (2010) | CCRT | Platinum based | Platinum based | 60 Gy/30# |
| Zatloukal (2004) | CCRT, SCRT | Cisplatin/vinorelbine | Cisplatin/vinorelbine | 60 Gy/30# |
†Updated in 2018, includes censored cases.
Not available.
Belani (2005a)—ECOG 2597.
Belani (2005b)—Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non-Small-Cell Lung Cancer: A Randomized Phase II lLocally Advanced Multi-Modality Protocol.
pRT—Palliative Radiotherapy.
cRT—Curative Radiotherapy without chemotherapy.
SCRT—Sequential chemoradiotherapy (induction or consolidation chemotherapy).
CCRT—Concurrent chemoradiotherapy (with or without sequential chemotherapy).